Action, not rhetoric, needed to reverse the opioid overdose epidemic

Journal of Law, Medicine and Ethics

Volumn 45, Issue 1_suppl, 2017, Pages 20-23

  Davis, Corey ^a   Green, Traci ^b,c   Beletsky, Leo ^d  

^a EAST CAROLINA UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CLINICAL DECISION MAKING; DRUG OVERDOSE; EPIDEMIC; HUMAN; LAW ENFORCEMENT; OPIATE ADDICTION; UNITED STATES;

ANALGESICS, OPIOID; CLINICAL DECISION-MAKING; DRUG OVERDOSE; EPIDEMICS; HUMANS; LAW ENFORCEMENT; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 85026577082     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1177/1073110517703310     Document Type: Article

References (26)

1. H. Park and M. Bloch, “How the Epidemic of Drug Overdose Death Ripples Across America,” New York Times, January 19, 2016.
2. K. McLean, “There’s Nothing Here”: Deindustrialization as Risk Environment for Overdose,” International Journal of Drug Policy no. 29 (2016): 19-26;
3. K. M. Keyes, M. Cerda, J. E. Brady, J. R. Havens, and S. Galea, “Understanding the Rural-Urban Differences in Nonmedical Prescription Opioid Use and Abuse in the United States,” American Journal of Public Health 104, no. 2 (2014): e52-e59;
4. A. Case and A. Deaton, “Rising Morbidity and Mortality in Midlife among White Non-Hispanic Americans in the 21st Century,” Proceedings of the Nationall Academy of Science 112, no. 49 (2015): 15078-15083;
5. L. R. Webster, S. Cochella, N. Dasgupta, K. L. Fakata, P. G. Fine, S. M. Fishman, T. Grey, E. M. Johnson, L. K. Lee, S. D. Passik, J. Peppin, C. A. Porucznik, A. Ray, S. H. Schnoll, R. L. Stieg, and W. Wakeland, “An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States,” Pain Medicine 12, Supp. 2 (2011): S26-35.
6. S. G. Kertesz, “Turning the Tide or Riptide? The Changing Opioid Epidemic,” Substance Abuse (November 18, 2016): 1-6.
7. H. Hedegaard, L. H. Chen, and M. Warner, “Drug-Poisoning Deaths Involving Heroin: United States, 2000-2013,” NCHS Data Brief 190 (2015):1-8.
8. T. C. Green, and M. Gilbert, “Counterfeit Medications and Fentanyl,” JAMA Intern Medicine 176, no. 10 (2016): 1557-1557.
9. P. Bourgois, “Crack and the Political Economy of Social Suffering,” Addiction Research & Theory 11, no. 1 (2009): 31-37.
10. C. S. Davis, T. C. Green, and N. D. Zaller, “Addressing the Overdose Epidemic Requires Timely Access to Data to Guide Interventions,” Drug and Alcohol Review 35, no. 4 (2016): 383-386.
11. A. Tsang, M. Von Korff, S. Lee, J. Alonso, E. Karam, M. C. Angermeyer, G. L. Borges, E. J. Bromet, K. Demytteneare, G. de Girolamo, R. de Graaf, O. Gureje, J. P. Lepine, J. M. Haro, D. Levinson, M. A. Oakley Browne, J. Posada-Villa, S. Seedat, and M. Watanabe, “Common Chronic Pain Conditions in Developed and Developing Countries: Gender and Age Differences and Comorbidity with Depression-Anxiety Disorders,” Journal of Pain 9, no. 10 (2008): 883-891.
12. J. Chiu, C. Davis, and S. Burris, “Access to Therapeutic Opioids: A Plan of Action for Donors, NGOs, and Governments,” Temple International & Comparative Law Journal 24, no. 2 (2011): 101-130;
13. G. Newshan and J. A. Staats, “Evidence-Based Pain Guidelines in HIV Care,” Journal of the Association of Nurses in AIDS Care 24, Supp. 1 (2013): S112-S126.
14. G. M. Franklin, “Opioids for Chronic Noncancer Pain: A Position Paper of the American Academy of Neurology,” Neurology 83, no. 14 (2014): 1277-1284.
15. D. Dowell, T. M. Haegerich, and R. Chou, “CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016,” JAMA 315, no. 15 (2016): 1624-1645.
16. A. Kolodny, D. T. Courtwright, C. S. Hwang, P. Kreiner, J. L. Eadie, T. W. Clark, and G. C. Alexander, “The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction,” Annual Review of Public Health 36 (2015): 559-574.
17. R. Bernabei, G. Gambassi, K. Lapane, F. Landi, C. Gatsonis, R. Dunlop, L. Lipsitz, K. Steel, and V. Mor, “Management of Pain in Elderly Patients with Cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology,” JAMA 279, no. 23 (1998): 1877-1882;
18. S. H. Meghani, E. Byun, and R. M. Gallagher, “Time to Take Stock: A Meta-analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States,” Pain Medicine 13, no. 2 (2012): 150-174.
19. C. S. Davis and D. Carr, “Physician Continuing Education to Reduce Opioid Misuse, Abuse, and Overdose: Many Opportunities, Few Requirements,” Drug and Alcohol Dependence 163 (2016): 100-107.
20. A. Y. Walley, Z. Xuan, H. H. Hackman, E. Quinn, M. Doe- Simkins, A. Sorensen-Alawad, S. Ruiz, and A. Ozonoff, “Opioid Overdose Rates and Implementation of Overdose Education and Nasal Naloxone Distribution in Massachusetts: Interrupted Time Series Analysis,” BMJ 346 (2013): f174.
21. C. S. Davis and D. Carr, “Legal Changes to Increase Access to Naloxone for Opioid Overdose Reversal in the United States,” Drug and Alcohol Dependence 157 (2015): 112-120.
22. L. Rutkow and C. S. Davis, “Opportunities to Improve Decision- Making about Opioid Prescribing,” Journal of General Internal Medicine 32, no. 1 (2017): 3-5.
23. J. Brody, “Effective Addiction Treatment,” New York Times, February 4, 2013.
24. S. A. Strathdee, L. Beletsky, and T. Kerr, “HIV, Drugs and the Legal Environment,” International Journal of Drug Policy 26, Supp. 1 (2015): S27-S32;
25. C. S. Davis, S. Burris, J. Kraut-Becher, K. G. Lynch, and D. Metzger, “Effects of an Intensive Street-Level Police Intervention on Syringe Exchange Program Use in Philadelphia, PA,” American Journal of Public Health 95, no. 2 (2005): 233-236.
26. B. Tempalski, P. L. Flom, S. R. Friedman, D. C. Des Jarlais, J. J. Friedman, C. McKnight, and R. Friedman, “Social and Political Factors Predicting the Presence of Syringe Exchange Programs in 96 US Metropolitan Areas,” American Journal of Public Health 97, no. 3 (2007): 437-447.